Xcout IntelAlector, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Alector, Inc. among biotech companies — ranked by similarity to what Alector, Inc. actually does, not by market-cap band.
Subscribe to see Alector, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Alector, Inc.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Alector, Inc. at a glance
Alector, Inc. is a biotech company headquartered in South San Francisco, United States. It is publicly listed (ALEC) with a market capitalisation of $230.9M. Xcout tracks 20 named people at Alector, Inc., including Neil Berkley (CFO & Chief Business Officer). Xcout recorded 11 job postings from Alector, Inc. in the last 90 days.
Alector, Inc. leadership
- Neil BerkleyCFO & Chief Business Officer
- Clare HuntChief People & Places Officer
- Danielle PasqualoneGeneral Counsel
- Arnon RosenthalCo-Founder, Chief Executive Officer & Director
- Hua LongSenior Vice President and Head of Research
- Hua Long DABTSenior VP & Head of Research
14 more named people on record for Alector, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Alector, Inc.
Xcout recorded 11 job postings from Alector, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Alector, Inc.'s hiring signals →
Top 12 Alector, Inc. competitors
Ranked by semantic similarity — how close each company is to Alector, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Biotechnology
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Biotechnology
FoldLogic Bio is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy. The company focuses on modulating the central nervous system's immune responses, specifically targeting microglial activity, alpha-synuclein, and TREM2 to halt disease progression.
Similar biotech company
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Biotechnology
Amygdala Neurosciences Inc is an independent small biopharmaceutical company headquartered in San Francisco, California. Its mission is to invent and develop first-in-class therapeutics.
Biotechnology
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Biotechnology
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Biotechnology
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Biotechnology
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
Similar biotech company
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Biotechnology
Cleave Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2011, the company develops enzyme inhibitors targeting valosin-containing protein (VCP)/p97 in protein homeostasis and cellular pathways to treat oncological and neurodegenerative conditions.
Biotechnology
AstronauTx is a clinical-stage biotechnology company headquartered in London, United Kingdom. Founded in 2019, the firm develops novel small-molecule drugs aimed at treating neurodegenerative conditions such as Alzheimer's disease by targeting glial cell dysfunction.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Alector, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Alector, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →